Login to Your Account

Pharma: Other News To Note

Monday, July 9, 2012
• Eli Lilly and Co., of Indianapolis, said it has met the FDA's requirements for pediatric exclusivity for Cymbalta (duloxetine HCl), gaining an additional six months of U.S. market exclusivity for the drug, which now will expire in December 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription